What is Erste Group Bank’s Estimate for NVO FY2026 Earnings?

Novo Nordisk A/S (NYSE:NVO) – Analysts at Erste Group Bank decreased their FY2026 earnings per share (EPS) estimates for shares of Novo Nordisk A/S in a research report issued on Thursday, October 8th. Erste Group Bank analyst H. Engel now anticipates that the company will post earnings per share of $3.29 for the year, down from their prior estimate of $3.43. The consensus estimate for Novo Nordisk A/S’s current full-year earnings is $3.42 per share. Erste Group Bank also issued estimates for Novo Nordisk A/S’s FY2027 earnings at $3.25 EPS.

NVO has been the topic of a number of other reports. Cfra downgraded shares of Novo Nordisk A/S from a “hold” rating to a “sell” rating and set a $38.00 price objective on the stock. in a research report on Tuesday, September 22nd. Weiss Ratings lowered shares of Novo Nordisk A/S from a “hold (c-)” rating to a “sell (d+)” rating in a report on Thursday, October 8th. Deutsche Bank Aktiengesellschaft reaffirmed a “sell” rating on shares of Novo Nordisk A/S in a research report on Tuesday, September 29th. UBS Group reaffirmed a “neutral” rating on shares of Novo Nordisk A/S in a research note on Monday, September 21st. Finally, Nordea Equity Research raised shares of Novo Nordisk A/S from a “hold” rating to a “buy” rating in a research note on Friday, June 19th. Five research analysts have rated the stock with a Buy rating, sixteen have given a Hold rating and five have issued a Sell rating to the stock. Based on data from MarketBeat.com, the company currently has an average rating of “Hold” and an average target price of $59.44.

Novo Nordisk A/S Stock Performance

Shares of NVO stock opened at $38.14 on Tuesday. The firm has a market capitalization of $170.30 billion, a price-to-earnings ratio of 9.47, a PEG ratio of 1.29 and a beta of 0.76. The stock has a fifty day moving average of $43.00 and a 200 day moving average of $43.91. Novo Nordisk A/S has a 52 week low of $35.12 and a 52 week high of $64.16. The company has a quick ratio of 0.66, a current ratio of 0.87 and a debt-to-equity ratio of 0.55.

Novo Nordisk A/S (NYSE:NVO) last posted its earnings results on Tuesday, June 30th. The company reported $0.94 earnings per share (EPS) for the quarter. The firm had revenue of $11.98 billion for the quarter. Novo Nordisk A/S had a return on equity of 58.61% and a net margin of 35.36%.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently made changes to their positions in the company. Arrowstreet Capital Limited Partnership purchased a new stake in shares of Novo Nordisk A/S in the 1st quarter worth approximately $287,660,000. Maverick Capital Ltd. purchased a new position in shares of Novo Nordisk A/S in the 1st quarter worth about $76,444,000. Public Employees Retirement System of Ohio purchased a new position in shares of Novo Nordisk A/S in the 1st quarter worth about $27,802,000. Rockefeller Capital Management L.P. raised its position in shares of Novo Nordisk A/S by 77.2% in the 4th quarter. Rockefeller Capital Management L.P. now owns 1,340,858 shares of the company’s stock worth $68,223,000 after purchasing an additional 584,275 shares during the last quarter. Finally, Pictet Asset Management Holding SA bought a new position in Novo Nordisk A/S in the 1st quarter worth about $17,800,000. Hedge funds and other institutional investors own 11.54% of the company’s stock.

Novo Nordisk A/S Cuts Dividend

The company also recently announced a dividend, which was paid on Tuesday, August 25th. Stockholders of record on Monday, August 17th were given a $0.5786 dividend. The ex-dividend date of this dividend was Monday, August 17th. This represents a dividend yield of 258.0%. This is a decrease from Novo Nordisk A/S’s previous dividend of $1.2751. Novo Nordisk A/S’s dividend payout ratio is currently 20.05%.

More Novo Nordisk A/S News

Here are the key news stories impacting Novo Nordisk A/S this week:

• Positive Sentiment: Novo Nordisk has repurchased approximately DKK 10.5 billion of shares under its DKK 15 billion program, supporting per-share value and signaling that management views the stock as undervalued. The company plans to allocate up to DKK 11.2 billion toward B shares through early 2027. Novo Nordisk’s Buyback Clears 10.5 Billion DKK as FDA Delay Clouds Denecimig Launch
• Positive Sentiment: Some valuation analysis argues that NVO could be materially undervalued after its steep multi-year decline, with the buyback potentially helping refocus investors on the company’s earnings power. Novo Nordisk Could Be 63% Undervalued Following Its Share Buyback
• Positive Sentiment: Novo Nordisk signed a non-exclusive license agreement with Ablexis to use its AlivaMab antibody-discovery platforms, expanding the tools available for developing future biologic medicines. The financial impact was not disclosed, so benefits are longer term. Ablexis Announces License Agreement with Novo

About Novo Nordisk A/S

Novo Nordisk A/S is a Denmark-based global pharmaceutical company focused on treatments for diabetes, obesity and other serious chronic diseases. Its portfolio includes injectable and oral medicines for diabetes, including insulin products and the GLP-1 therapies Ozempic and Rybelsus, as well as the obesity treatment Wegovy.

The company also develops and markets products for rare blood disorders, including hemophilia, along with growth hormone therapies and hormone replacement treatments.